CAREDX INC (CDNA)
Health Care · Molecular Diagnostics · NASDAQ
CareDx is a precision medicine leader providing diagnostic testing, digital health tools, and patient support services to improve outcomes for transplant and oncology patients.
What CAREDX INC does
CareDx is a precision medicine company focused on the transplant, specialty oncology, and cell therapy markets. The company provides non-invasive molecular testing, clinical practice management software, AI-powered data and analytics tools, and patient support solutions to help clinicians manage patients and improve transplant outcomes. Its testing portfolio includes donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling solutions for kidney, heart, and lung transplant patients, as well as blood-based tests for HPV-mediated cancers.
Themes: transplant diagnostics, precision medicine, cell-free DNA testing, digital health solutions, oncology diagnostics, genomics-based informatics
Fundamentals
- Price$48.61 as of 2026-08-21 close
- Market cap$2.5B as of 2026-08-21
- 1-year return+288.6% 2025-08-21 close $12.51 → 2026-08-21 close $48.61
- P/E22.08 as of 2026-08-24
- Net margin+24.2% as of 2026-08-24
- Gross margin+70.6% as of 2026-08-24
- ROE+32.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+34.4% as of 2026-08-24
- Revenue CAGR (3y)+5.7% SEC XBRL
- Beta2.45 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How CDNA compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CDNA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
49.2 #848 of 1,704 scored · #149 of 240 in Health Care
Trend 90th: a strong uptrend, with buyers in control; volume and participation 79th: it gapped 8.0% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 23rd: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How CAREDX INC looks technically
CAREDX INC (CDNA) is trading 108.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 169 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 54, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It just made a new 20-day high, pushing above its recent trading range. It is 2.3% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 108.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +108.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $35.67 | $35.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $23.27 | $23.27 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 49.76. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 169 trading days ago — a "golden cross", a bullish long-term signal | 169 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 54, with buyers in control | 53.7 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70) | 71.7 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($44.57 to $48.72) — its "stochastic" reading is 97 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 97.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.76 | $49.76 |
|---|---|---|
| From the 52-week high | it is 2.3% below its 52-week high (its highest price of the past year) | -2.3% |
| Above the 52-week low | it is 331.2% above its 52-week low (its lowest price of the past year) | +331.3% |
| Below the 52-week high | it is 2.3% below its highest point of the past year | 2.3% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $99.83 (set on 2021-01-20) | $99.83 |
| Given back of the 52-week move | over the past year its closes ranged ($11.57 to $48.61), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $24.53 to $25.72. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 51.3% below its all-time high | -51.3% |
| Nearest price level | it is trading 43.5% above a support level at $27.44 — a price it turned at twice since 2024-09-24, most recently on 2026-07-08. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -43.5% |
| All-time low | its lowest closing price on record is $0.76 (set on 2017-04-28) | $0.76 |
| Above the all-time low | it is 6296.1% above its all-time low | +6,296% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.18 between its high and its low — about 4.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.18 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $36.08 and $52.94 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $36.08 – $44.51 – $52.94 |
| Typical daily range (% of price) | its price moves about 4.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.5% |
| Stretch from the 200-day average | it is trading 11.6 daily ranges above its 200-day average price (108.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 8.0% above the previous close 14 sessions ago and has not traded back through the level it left behind at 43.71 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +8.0% |
| Gap filled | a 2.3% gap up opened on 2026-07-24 has been "filled" 20 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 20 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +5.26% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 23.8 percentage points (the stock gained 26.1% while the market gained 2.3%) | +23.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 122.3 percentage points (the stock gained 125.4% while the market gained 3.1%) | +122.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 147.5 percentage points (the stock gained 158.6% while the market gained 11.1%) | +147.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 268.1 percentage points (the stock gained 288.6% while the market gained 20.5%) | +268.1% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 50% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.7% of the share price. | +49.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 79% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $27.17 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +78.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $45.79 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +6.2% |
Price levels it has turned at before
CDNA last closed at $48.61 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $27.44 | Support | 43.5% below the last close | turned there twice · 2024-09-24 to 2026-07-08 |
| $26.17 | Support | 46.2% below the last close | turned there three times · 2024-09-06 to 2025-01-14 |
| $23.19 | Support | 52.3% below the last close | turned there twice · 2026-04-17 to 2026-04-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $49.76.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.86 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$52.33 range $40.00 – $64.00; median $52.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CDNA
- Consensus EPS estimate$0.25 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on coverage policies and reimbursement from third-party insurers and government payers.","Requirement for significant ongoing investment in clinical studies to generate supporting data for tests.","Operating results may be volatile due to the complexity of collecting revenue from payers without established coverage."]
What changed in the latest 10-Q
AI-assisted comparison of CDNA's 10-Q filed 2026-04-28 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-28) references audited consolidated financial statements for fiscal year ended December 31, 2025, filed February 25, 2026 (versus December 31, 2024, filed February 28, 2025 in older filing)
- Newer filing (2026-04-28) states company is 'dedicated to improving outcomes for transplant patients and advancing organ health' with emphasis on 'deliver solutions designed to empower clinicians'
- Newer filing (2026-04-28) adds 'Average revenue per test of approximately $1,660 including approximately $14 million in prior period revenue' to Q1 2026 highlights
- Newer filing (2026-04-28) reports 'Cash flow from operations of $4 million' in highlights (metric not included in older filing's Q3 2025 highlights)
- Removed:
- Older filing (2025-11-04) mentions 'AlloCell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy' and 'multiple biopharma research partnerships' – not mentioned in newer filing
- Older filing (2025-11-04) includes cash position detail: 'Cash, cash equivalents and marketable securities of $194.2 million as of September 30, 2025, net of a $25.6 million share repurchase carried out during the quarter; no debt' – not included in newer filing's highlights
- Older filing (2025-11-04) states 'continued successful implementation of our pharmacy solutions' while newer filing (2026-04-28) omits 'pharmacy solutions' from this phrase
- Reworded:
- Older filing (2025-11-04) describes company as 'a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions' versus newer filing (2026-04-28) as 'a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health'
- Testing services revenue percentages: newer filing (2026-04-28) shows '78% of our total revenue for each of the three months ended March 31, 2026, and 73%' for 2025 comparison; older filing (2025-11-04) shows '72% of our total revenue for each of the three and nine months ended September 30, 2025, and 73% and 75%' for 2024 comparisons
- Product revenue percentages: newer filing (2026-04-28) reports '9% of our total revenue for the three months ended March 31, 2026, and 13%' for 2025 comparison; older filing (2025-11-04) reported '12% and 13%' for 2025 periods and '12%' for 2024 periods
- Patient and digital solutions revenue: newer filing (2026-04-28) states '14% of our total revenue for the three months ended March 31, 2026, and 14%' versus older filing (2025-11-04) showing '15% of our total revenue for each of the three and nine months ended September 30, 2025, and 14% and 13%'
- Older filing (2025-11-04) references 'continued successful implementation of our pharmacy solutions, Ottr, MedActionPlan and XynQAPI' while newer filing (2026-04-28) states 'continued successful implementation of our pharmacy solutions' is removed and lists only 'Ottr, MedActionPlan and XynQAPI software businesses'
- Notes:
- The two filings cover different fiscal periods (Q1 2026 versus Q3 2025), making some numerical comparisons inherently different rather than changed
- Text appears truncated in both source documents at the 'Timing of Research and Development Expenses' section, limiting complete comparison of that subsection
Risk Factors
- Added:
- Added comparison of net income for Q1 2026 ($2.8 million) versus Q1 2025 net loss ($10.4 million) in newer filing (filed 2026-04-28)
- Added statement that company 'have not consistently achieved profitability' and cannot assure sustained profitability on quarterly or annual basis (filed 2026-04-28)
- Added detailed discussion of February 3, 2026 'Consolidated Appropriations Act, 2026' amending PAMA law, including reporting requirements for private payor rates from January 1 – June 30, 2025, with reporting period May-July 2026, and statement that reporting is not anticipated to materially impact current Medicare pricing (filed 2026-04-28)
- Added statement that on November 25, 2025, CMS issued final determination to cross-walk AlloSure (0540U) to CPT code 0493U, effective January 1, 2026 at approximately $2,753 (filed 2026-04-28)
- Removed:
- Removed reference to 'three months ended September 30, 2025' with net income of $1.7 million (filed 2025-11-04)
- Removed accumulated deficit figure of $719.0 million as of September 30, 2025 (filed 2025-11-04)
- Removed statement that 'In June 2025, we recommended that CMS price our AlloSure tests consistent with the pricing for PLA Code 0493U' and associated conditional language about what 'If CMS adopts this recommendation' (filed 2025-11-04)
- Removed statement 'The final reimbursement rate for PLA Code 0540U is expected to be listed on the Clinical Laboratory Fee Schedule starting January 1, 2026. However, we cannot predict final pricing under the new CPT code, including whether CMS will agree with our recommendation.' (filed 2025-11-04)
- Removed entire paragraph beginning 'On July 17, 2025, MolDX and Noridian released a new draft proposed revision...' discussing the Proposed LCD with new coverage criteria, utilization limitations, and bundled payment concept (filed 2025-11-04)
- Reworded:
- Changed Medicare revenue percentage from '48% of testing services revenue' for three months ended September 30, 2025 to '35% of testing services revenue' for three months ended March 31, 2026 (filed 2026-04-28 vs 2025-11-04)
- Changed 'represented' to 'represente d' in Medicare revenue percentage statement (appears to be formatting/transcription artifact in newer filing)
- Expanded introductory language to add phrase about 'These disclosures reflect management's beliefs and opinions as to factors that could materially and adversely affect the Company' and 'References to past events are provided by way of example only...' (filed 2026-04-28)
- Notes:
- Text appears truncated at end of both newer and older filings, limiting complete comparison of Medicare risk factor section
- Accumulated deficit changed from $719.0 million (Sept 30, 2025) to $732.5 million (March 31, 2026), reflecting passage of time and financial activity
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 10 sells ($8M) — 2 selling insiders
- Last 180 days0 buys · 14 sells ($9M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-16. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CDNA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding CDNA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 11,009,913
- Reported value $191,132,101
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CDNA had 6,135,225 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CDNA had 11.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.25 days to cover at the same settlement.
- Reported short interest (shares) 6,135,225
- Short interest (% of shares outstanding) 11.9%
- Prior settlement (shares) 6,187,364
- Reported change -0.84%
- Days to cover (reported) 4.25
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Natera (NTRA)
- Veracyte (VCYT)
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Illumina (ILMN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CDNA vs…
CAREDX INC is found in…
Frequently asked questions
What does CAREDX INC (CDNA) do?
CareDx is a precision medicine company focused on the transplant, specialty oncology, and cell therapy markets. The company provides non-invasive molecular testing, clinical practice management software, AI-powered data and analytics tools, and patient support solutions to help clinicians manage patients and improve transplant outcomes.
What sector is CAREDX INC (CDNA) in?
CAREDX INC (CDNA) is classified in the Health Care sector. Its industry is Molecular Diagnostics. It trades on NASDAQ.
Who are CAREDX INC's (CDNA) competitors?
Notable peers of CAREDX INC (CDNA) include Natera, Veracyte, Exact Sciences, Guardant Health and Illumina. This peer set is informational only — not financial advice.
Is CAREDX INC (CDNA) overbought or oversold right now?
CAREDX INC (CDNA) is currently in overbought territory (its 14-day RSI is 72, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CDNA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.